

Singapore MOH includes Roche's spinal muscular atrophy (SMA) drug in MAF framework

01 August 2024 | News



Roche's EVRYSDI® (risdiplam) drug is the first treatment for SMA included on the MAF List

EVRYSDI[®] (risdiplam) has been added to the Singapore Ministry of Health's (MOH) list of medicines covered by the Medication Assistance Fund (MAF) Subsidy Framework, making it the first treatment for spinal muscular atrophy (SMA) to be included.

Under the MAF Subsidy Framework, Singaporean patients with SMA meeting the clinical criteria, are eligible for subsidised treatment with Evrysdi in public healthcare institutions.

SMA is a rare neuromuscular disorder that causes muscle weakness and wasting, leading to symptoms such as breathing difficulties and loss of motor function. MAF subsidies for Evrysdi will improve access to the drug for SMA treatment in both pediatric and adult patient populations.

The Ministry of Health Drug Advisory Committee recommended Evrysdi (risdiplam) to be added to the MAF List to improve access to SMA treatment for children and adults with Types 1, 2 and 3 SMA across four patient groups; it is the first treatment for SMA to be included on the MAF List

Judy Wee, Executive Director, Muscular Dystrophy Association (Singapore), said "The inclusion of Evrysdi on MAF is a milestone that will have an impact far beyond treatment of the disease. With more affordable and effective treatment, patients with SMA have the potential to retain or reclaim their independence, while alleviating some of the burden placed on caregivers and loved ones."

Evrysdi is now approved in more than 100 countries with over 15,000 patients treated globally.